In a report released yesterday, Boris Peaker from Cowen & Co. maintained a Buy rating on Surface Oncology Inc (SURF). The company’s shares closed yesterday at $4.33, close to its 52-week low of $3.45.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.4% and a 41.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
The the analyst consensus on Surface Oncology Inc is currently a Moderate Buy rating.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.18 and a one-year low of $3.45. Currently, Surface Oncology Inc has an average volume of 57.78K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Surface Oncology, Inc. is a clinical-stage immuno-oncology company, which focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.
